Literature DB >> 17391322

CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.

Rajeev K Mehlotra1, Moses J Bockarie, Peter A Zimmerman.   

Abstract

AIMS: To determine the prevalence of the novel CYP2B6 functional polymorphism 983T>C in Papua New Guinea where HIV/AIDS poses a significant health problem.
METHOD: We genotyped Papua New Guineans (PNG, n = 174), West Africans (WA, n = 170), and North Americans (NA, n = 361).
RESULTS: The polymorphism was absent in PNG, while its overall frequency was 4.7% in WA. Among NA, the polymorphism was present in African-Americans (7.5%) and Hispanic-Americans (1.1%) but not in Caucasian-Americans and Asian-Americans. Haplotype analysis indicated that 983T>C was present alone as the CYP2B6*18 allele in WA and African-Americans.
CONCLUSIONS: Significant interethnic differences occur at the CYP2B6 locus, which may influence treatment outcomes with efavirenz.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391322      PMCID: PMC2000644          DOI: 10.1111/j.1365-2125.2007.02884.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

2.  Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles.

Authors:  Thomas Lang; Kathrin Klein; Tanja Richter; Arne Zibat; Reinhold Kerb; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  J Pharmacol Exp Ther       Date:  2004-06-09       Impact factor: 4.030

3.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Authors:  David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta
Journal:  AIDS       Date:  2004-12-03       Impact factor: 4.177

4.  Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

5.  Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

Authors:  D A Erickson; G Mather; W F Trager; R H Levy; J J Keirns
Journal:  Drug Metab Dispos       Date:  1999-12       Impact factor: 3.922

6.  Efavirenz intoxication due to slow hepatic metabolism.

Authors:  B Hasse; H F Günthard; G Bleiber; M Krause
Journal:  Clin Infect Dis       Date:  2005-01-07       Impact factor: 9.079

Review 7.  Nevirapine in the treatment of HIV.

Authors:  Ana Milinkovic; Esteban Martínez
Journal:  Expert Rev Anti Infect Ther       Date:  2004-06       Impact factor: 5.091

Review 8.  Efavirenz for HIV-1 infection in adults: an overview.

Authors:  Claude Fortin; Veronique Joly
Journal:  Expert Rev Anti Infect Ther       Date:  2004-10       Impact factor: 5.091

9.  Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

Authors:  Kiyoto Tsuchiya; Hiroyuki Gatanaga; Natsuo Tachikawa; Katsuji Teruya; Yoshimi Kikuchi; Munehiro Yoshino; Takeshi Kuwahara; Takuma Shirasaka; Satoshi Kimura; Shinichi Oka
Journal:  Biochem Biophys Res Commun       Date:  2004-07-09       Impact factor: 3.575

10.  Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.

Authors:  Joseph F Solus; Brenda J Arietta; James R Harris; David P Sexton; John Q Steward; Chara McMunn; Patrick Ihrie; Janelle M Mehall; Todd L Edwards; Elliott P Dawson
Journal:  Pharmacogenomics       Date:  2004-10       Impact factor: 2.533

View more
  38 in total

1.  Bioactivation of chlorpyrifos by CYP2B6 variants.

Authors:  Alice L Crane; Kathrin Klein; James R Olson
Journal:  Xenobiotica       Date:  2012-07-10       Impact factor: 1.908

2.  PharmGKB summary: very important pharmacogene information for CYP2B6.

Authors:  Caroline F Thorn; Jatinder K Lamba; Vishal Lamba; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-08       Impact factor: 2.089

Review 3.  Human Genetic Variation and HIV/AIDS in Papua New Guinea: Time to Connect the Dots.

Authors:  Rajeev K Mehlotra
Journal:  Curr HIV/AIDS Rep       Date:  2018-12       Impact factor: 5.071

Review 4.  African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping.

Authors:  Michael C Campbell; Sarah A Tishkoff
Journal:  Annu Rev Genomics Hum Genet       Date:  2008       Impact factor: 8.929

5.  Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success.

Authors:  Rajeev K Mehlotra; Vinay K Cheruvu; Melinda J Blood Zikursh; Rebekah L Benish; Michael M Lederman; Robert A Salata; Barbara Gripshover; Grace A McComsey; Michelle V Lisgaris; Scott Fulton; Carlos S Subauste; Richard J Jurevic; Chantal Guillemette; Peter A Zimmerman; Benigno Rodriguez
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

Review 6.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

Review 7.  Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Authors:  Awewura Kwara; Geetha Ramachandran; Soumya Swaminathan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

8.  Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

Authors:  Christoph Wyen; Heidy Hendra; Martin Vogel; Christian Hoffmann; Heribert Knechten; Norbert H Brockmeyer; Johannes R Bogner; Jürgen Rockstroh; Stefan Esser; Hans Jaeger; Thomas Harrer; Stefan Mauss; Jan van Lunzen; Nicole Skoetz; Alexander Jetter; Christiane Groneuer; Gerd Fätkenheuer; Saye H Khoo; Deirdre Egan; David J Back; Andrew Owen
Journal:  J Antimicrob Chemother       Date:  2008-02-14       Impact factor: 5.790

9.  Clinical and genetic modifiers of long-term survival in heart failure.

Authors:  Sharon Cresci; Reagan J Kelly; Thomas P Cappola; Abhinav Diwan; Daniel Dries; Sharon L R Kardia; Gerald W Dorn
Journal:  J Am Coll Cardiol       Date:  2009-07-28       Impact factor: 24.094

Review 10.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.

Authors:  Hongbing Wang; Leslie M Tompkins
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.